Categories
Change Password!
Reset Password!
The nucleotide analog under
trials against Ebola virus infection and HIV-1 protease inhibitors could be
used to manage COVID-19 but these cannot be used to reverse the highly
pathogenic infection.
The COVID-2019 also known as Novel Coronavirus or SARS-CoV-2 outbreak has become the international health emergency. As it is increasing at a very faster rate and demand of the time is to have therapeutic approaches which can be used to manage this pandemic. Miguel Angel Martinez performed a minireview for the therapeutic compounds available for the management of COVID-2019.
The previously characterized medicinal compounds to
control SARS-CoV, 2003 and MERS-CoV, 2012 could be active against COVID-19.
Remdesivir (GS-5734), a nucleotide analog which is currently in trials for
Ebola virus infections is the most promising compound. This compound proved its
efficacy in animal models by inhibits the replication of the MERS-CoV and
SARS-CoV. Moreover, in SARS-CoV patients the combination of HIV-1 protease
inhibitors, lopinavir/ritonavir, and interferon-beta (LPV/RTV-INFb) found
efficacious.
In the transgenic humanized mice model the remdesivir
found to be more effective than LPV/RTV-INFb against MERS-CoV. The high
mortality rates due to the SARS-CoV-2, SARS-CoV, MERS-CoV indicate that their
pathogenesis can be attributed to the pro-inflammatory response. But it is not
clear whether to target inflammatory state or not. This review was aimed to
provide summary of therapeutic options available against COVID-19.
Antimicrobial Agents and Chemotherapy
Compounds With Therapeutic Potential Against Novel Respiratory 2019 Coronavirus
Miguel Angel Martinez
Comments (1)